Sanofi (SNY) Expected to Announce Earnings of $0.69 Per Share

Wall Street brokerages forecast that Sanofi (NYSE:SNY) will announce earnings per share (EPS) of $0.69 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Sanofi’s earnings. The lowest EPS estimate is $0.67 and the highest is $0.71. Sanofi posted earnings of $0.67 per share during the same quarter last year, which would indicate a positive year over year growth rate of 3%. The business is expected to report its next earnings results on Wednesday, February 14th.

According to Zacks, analysts expect that Sanofi will report full-year earnings of $3.28 per share for the current financial year, with EPS estimates ranging from $3.18 to $3.42. For the next financial year, analysts anticipate that the firm will report earnings of $3.41 per share, with EPS estimates ranging from $3.22 to $3.66. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow Sanofi.



A number of brokerages recently weighed in on SNY. Barclays PLC raised shares of Sanofi from an “underweight” rating to an “equal weight” rating in a report on Wednesday. Argus restated a “buy” rating and issued a $55.00 price objective on shares of Sanofi in a research note on Friday, September 1st. upgraded Sanofi from a “reduce” rating to a “hold” rating in a research note on Wednesday, August 30th. BidaskClub upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Saturday, August 5th. Finally, Cowen and Company restated a “market perform” rating and issued a $52.00 price objective (up from $46.00) on shares of Sanofi in a research note on Tuesday, August 1st. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the company’s stock. Sanofi has an average rating of “Hold” and an average price target of $53.50.

Sanofi (NYSE:SNY) traded down $0.11 on Friday, reaching $44.54. 661,417 shares of the company’s stock were exchanged, compared to its average volume of 1,520,238. The company has a quick ratio of 1.16, a current ratio of 1.59 and a debt-to-equity ratio of 0.26. The stock has a market cap of $112,540.00, a P/E ratio of 14.09, a price-to-earnings-growth ratio of 2.46 and a beta of 0.88. Sanofi has a 1 year low of $38.45 and a 1 year high of $50.65.

In other Sanofi news, major shareholder Sanofi bought 60,595 shares of the firm’s stock in a transaction that occurred on Wednesday, August 23rd. The stock was bought at an average price of $478.98 per share, for a total transaction of $29,023,793.10. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.00% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of SNY. Bank of Nova Scotia Trust Co. bought a new position in shares of Sanofi during the third quarter valued at $125,000. Parallel Advisors LLC increased its holdings in shares of Sanofi by 42.5% during the second quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock valued at $139,000 after acquiring an additional 875 shares in the last quarter. YorkBridge Wealth Partners LLC increased its holdings in shares of Sanofi by 33.7% during the second quarter. YorkBridge Wealth Partners LLC now owns 3,076 shares of the company’s stock valued at $147,000 after acquiring an additional 776 shares in the last quarter. Eagle Ridge Investment Management bought a new position in shares of Sanofi during the second quarter valued at $160,000. Finally, Bronfman E.L. Rothschild L.P. increased its holdings in shares of Sanofi by 142.8% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,567 shares of the company’s stock valued at $171,000 after acquiring an additional 2,098 shares in the last quarter. Institutional investors and hedge funds own 9.36% of the company’s stock.

WARNING: “Sanofi (SNY) Expected to Announce Earnings of $0.69 Per Share” was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://ledgergazette.com/2017/11/17/sanofi-sny-expected-to-announce-earnings-of-0-69-per-share.html.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Get a free copy of the Zacks research report on Sanofi (SNY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

Sanofi (SNY) Expected to Announce Earnings of $0.69 Per Share

Wall Street brokerages forecast that Sanofi (NYSE:SNY) will announce earnings per share (EPS) of $0.69 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Sanofi’s earnings. The lowest EPS estimate is $0.67 and the highest is $0.71. Sanofi posted earnings of $0.67 per share during the same quarter last year, which would indicate a positive year over year growth rate of 3%. The business is expected to report its next earnings results on Wednesday, February 14th.

According to Zacks, analysts expect that Sanofi will report full-year earnings of $3.28 per share for the current financial year, with EPS estimates ranging from $3.18 to $3.42. For the next financial year, analysts anticipate that the firm will report earnings of $3.41 per share, with EPS estimates ranging from $3.22 to $3.66. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow Sanofi.



A number of brokerages recently weighed in on SNY. Barclays PLC raised shares of Sanofi from an “underweight” rating to an “equal weight” rating in a report on Wednesday. Argus restated a “buy” rating and issued a $55.00 price objective on shares of Sanofi in a research note on Friday, September 1st. upgraded Sanofi from a “reduce” rating to a “hold” rating in a research note on Wednesday, August 30th. BidaskClub upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Saturday, August 5th. Finally, Cowen and Company restated a “market perform” rating and issued a $52.00 price objective (up from $46.00) on shares of Sanofi in a research note on Tuesday, August 1st. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the company’s stock. Sanofi has an average rating of “Hold” and an average price target of $53.50.

Sanofi (NYSE:SNY) traded down $0.11 on Friday, reaching $44.54. 661,417 shares of the company’s stock were exchanged, compared to its average volume of 1,520,238. The company has a quick ratio of 1.16, a current ratio of 1.59 and a debt-to-equity ratio of 0.26. The stock has a market cap of $112,540.00, a P/E ratio of 14.09, a price-to-earnings-growth ratio of 2.46 and a beta of 0.88. Sanofi has a 1 year low of $38.45 and a 1 year high of $50.65.

In other Sanofi news, major shareholder Sanofi bought 60,595 shares of the firm’s stock in a transaction that occurred on Wednesday, August 23rd. The stock was bought at an average price of $478.98 per share, for a total transaction of $29,023,793.10. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.00% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of SNY. Bank of Nova Scotia Trust Co. bought a new position in shares of Sanofi during the third quarter valued at $125,000. Parallel Advisors LLC increased its holdings in shares of Sanofi by 42.5% during the second quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock valued at $139,000 after acquiring an additional 875 shares in the last quarter. YorkBridge Wealth Partners LLC increased its holdings in shares of Sanofi by 33.7% during the second quarter. YorkBridge Wealth Partners LLC now owns 3,076 shares of the company’s stock valued at $147,000 after acquiring an additional 776 shares in the last quarter. Eagle Ridge Investment Management bought a new position in shares of Sanofi during the second quarter valued at $160,000. Finally, Bronfman E.L. Rothschild L.P. increased its holdings in shares of Sanofi by 142.8% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,567 shares of the company’s stock valued at $171,000 after acquiring an additional 2,098 shares in the last quarter. Institutional investors and hedge funds own 9.36% of the company’s stock.

WARNING: “Sanofi (SNY) Expected to Announce Earnings of $0.69 Per Share” was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://ledgergazette.com/2017/11/17/sanofi-sny-expected-to-announce-earnings-of-0-69-per-share.html.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Get a free copy of the Zacks research report on Sanofi (SNY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply